EUVIMEDEUVIMED entdecken
Crossref

O-09: Diagnostic performance of CGM to identify stage 2 and stage 3 type 1 diabetes in the finnish DIPP-study

R Squintani, E Lahti, H Kontola, J Koskenniemi, J Kero, T Honkanen, T Pokka, J Toppari, R Veijola

Hormone Research in Paediatrics · 04.11.2026 · 99 (Supplement_4)

DOI: 10.1159/hrp/adaag020.009 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Hormone Research in Paediatrics, online erschienen am 04.11.2026. Verfasst von R Squintani und 8 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Continuous glucose monitoring (CGM) were proposed as diagnostic tools for staging type 1 diabetes.

Objectives

We explored the performance of CGM metrics to diagnose stage 2 and stage 3 type 1 diabetes.

Methods

In the Finnish Type 1 Diabetes Prediction and Prevention (DIPP) Study, 253 CGMs were evaluated, collected between 2020 and 2024 during the regular follow-up, in 149 genetically susceptible individuals (median age at first CGM 9.7 years, range 1.6 – 25.4). They were also monitored with OGTT and HbA1c. Participants were persistently positive for multiple islet autoantibodies (n=88), or a single autoantibody (n=33), or autoantibody negative (n=28). Stages of type 1 diabetes were determined according to the American Diabetes Association criteria. Receiver operating characteristic (ROC) analyses were used to assess the discriminatory performance of CGM thresholds in defining stage 2 and stage 3 type 1 diabetes.

Results

In the first CGM recorded (n=149), higher glucose variability (standard deviation, and coefficient of variation) was observed in individuals positive for multiple islet autoantibodies (median SD 1.2 mmol/L and median CV 20.3%) compared to those single autoantibody positive (0.9 mmol/L and 15.4%, p<0.001) and those with no autoantibodies (0.9 mmol/L and 14.5%, p<0.001). Mean sensor glucose levels did not differ between the three groups (5.9, 6.0, and 6.0 mmol/L; p=0.726). In ROC analyses to diagnose stage 2 type 1 diabetes, TA140 and time spent above 8.9 mmol/L (TA160) showed good discriminatory performance, with AUCs of 0.72 and 0.76 at the optimal cut-off of 5.2% and 1.8%, with sensitivities of 87% and 80%, and specificities of 52% and 65%, respectively. To diagnose stage 3 type 1 diabetes, both TA140 and TA160 showed high discriminatory performance, with AUCs of 0.83 and 0.84 at the optimal cut-off of 16.5% and 4.5%, sensitivities of 66% and 79%, and specificities of 89% and 80%, respectively.

Conclusions

CGM is not sufficient as a stand-alone tool to define stages of type 1 diabetes.

Zitieren

APA

Squintani, R., Lahti, E., Kontola, H., Koskenniemi, J., Kero, J., Honkanen, T., Pokka, T., Toppari, J., & Veijola, R. (2026). O-09: Diagnostic performance of CGM to identify stage 2 and stage 3 type 1 diabetes in the finnish DIPP-study. Hormone Research in Paediatrics, 99(Supplement_4). https://doi.org/10.1159/hrp/adaag020.009

Vancouver

Squintani R, Lahti E, Kontola H, Koskenniemi J, Kero J, Honkanen T, et al. O-09: Diagnostic performance of CGM to identify stage 2 and stage 3 type 1 diabetes in the finnish DIPP-study. Hormone Research in Paediatrics. 2026;99(Supplement_4). doi:10.1159/hrp/adaag020.009

BibTeX
@article{Squintani2026,
  author = {Squintani, R and Lahti, E and Kontola, H and Koskenniemi, J and Kero, J and Honkanen, T and Pokka, T and Toppari, J and Veijola, R},
  title = {O-09: Diagnostic performance of CGM to identify stage 2 and stage 3 type 1 diabetes in the finnish DIPP-study},
  journal = {Hormone Research in Paediatrics},
  year = {2026},
  volume = {99},
  number = {Supplement_4},
  doi = {10.1159/hrp/adaag020.009}
}
Kostenlos starten →